Ivabradine LVEF Requirement
Ivabradine requires a left ventricular ejection fraction (LVEF) of ≤35% for initiation in patients with heart failure. This threshold is consistently specified across both the 2022 AHA/ACC/HFSA guidelines and FDA labeling 1, 2, 3.
Specific Eligibility Criteria
Beyond the LVEF threshold, patients must meet ALL of the following criteria:
- LVEF ≤35% (not 40%, not "reduced" - specifically 35% or less)
- Sinus rhythm (contraindicated in atrial fibrillation)
- Resting heart rate ≥70 bpm at rest
- NYHA class II-III symptomatic chronic heart failure (stable, not acute decompensated)
- On maximally tolerated beta-blocker OR have a contraindication to beta-blockers
- Stable for at least 4 weeks on guideline-directed medical therapy
Critical Context from the SHIFT Trial
The landmark SHIFT trial that established ivabradine's efficacy enrolled patients with LVEF ≤35%, and the mean LVEF in that study was 29% 1, 3. The primary benefit was reduction in heart failure hospitalization, NOT mortality reduction - cardiovascular death was not significantly improved 3. This is important because the drug's indication is specifically for reducing hospitalization risk, not extending survival.
Common Pitfall: Beta-Blocker Optimization
A critical caveat: In SHIFT, only 25% of patients were on optimal beta-blocker doses 1. Beta-blockers must be uptitrated to maximum tolerated doses BEFORE considering ivabradine, as beta-blockers have proven mortality benefits that ivabradine lacks 1. The main reasons patients in SHIFT weren't at target beta-blocker doses were hypotension (45%), fatigue (32%), dyspnea (14%), and dizziness (12%) 3.
Do Not Use If:
- LVEF >35%
- Atrial fibrillation or atrial flutter (ivabradine increases atrial fibrillation risk) 3
- Heart rate <70 bpm at rest
- Acute decompensated heart failure 3
- Pacemaker-dependent patients 3
The LVEF cutoff of ≤35% is absolute and non-negotiable based on the evidence that supports this medication's approval and guideline recommendations.